{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:28:57Z","timestamp":1788866937629,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016616","name":"Cystic Fibrosis Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016616","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["ZEMANI20Y7"],"award-info":[{"award-number":["ZEMANI20Y7"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["LORENZ22H0"],"award-info":[{"award-number":["LORENZ22H0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MORAN19GE3"],"award-info":[{"award-number":["MORAN19GE3"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["WOOD19GE0"],"award-info":[{"award-number":["WOOD19GE0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jcf.2025.03.007","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T08:19:32Z","timestamp":1741940372000},"page":"755-758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hemoglobin A1c in youth and adults with cystic fibrosis related diabetes decreases after elexacaftor-tezacaftor-ivacaftor"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1131-2363","authenticated-orcid":false,"given":"Colleen","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9909-6724","authenticated-orcid":false,"given":"Amir","family":"Moheet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7087-8570","authenticated-orcid":false,"given":"Tim","family":"Vigers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-6267","authenticated-orcid":false,"given":"Andrea","family":"Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8044-3850","authenticated-orcid":false,"given":"Andrea","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinor","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Zemanick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3067-7672","authenticated-orcid":false,"given":"Christine L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jcf.2025.03.007_bib0001","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.jcf.2025.03.007_bib0002","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","article-title":"Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex","volume":"191","author":"Lewis","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"10.1016\/j.jcf.2025.03.007_bib0003","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.03.007_bib0004","article-title":"Glycemia and beta-cell function before and after elexacaftor\/tezacaftor\/ivacaftor in youth and adults with cystic fibrosis","volume":"30","author":"Chan","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.jcf.2025.03.007_bib0005","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","author":"Petersen","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2025.03.007_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101466","article-title":"Effects of elexacaftor \/tezacaftor \/ ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes","volume":"49","author":"Grancini","year":"2023","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jcf.2025.03.007_bib0007","article-title":"Decline in HbA1c during the first year of elexacaftor\/tezacaftor\/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: decline in HbA1c after elexacaftor\/tezacaftor\/ivacaftor treatment","author":"Nielsen","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2025.03.007_bib0008","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.03.007_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study","volume":"10","author":"Korten","year":"2022","journal-title":"Front Pediatr"},{"issue":"4","key":"10.1016\/j.jcf.2025.03.007_bib0010","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"Improved glucose tolerance after initiation of Elexacaftor \/Tezacaftor \/ Ivacaftor in adults with cystic fibrosis","volume":"22","author":"Steinack","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.03.007_bib0011","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad443","article-title":"Preservation of beta-cell function in pancreatic insufficient cystic fibrosis with highly effective CFTR modulator therapy","author":"Flatt","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcf.2025.03.007_bib0012","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cca.2012.12.026","article-title":"The long and winding road to optimal HbA1c measurement","volume":"418","author":"Little","year":"2013","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/j.jcf.2025.03.007_bib0013","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000530571","article-title":"Improvements in glucose regulation in children and young people with cystic fibrosis-related diabetes following initiation of elexacaftor\/tezacaftor\/ivacaftor","volume":"97","author":"Park","year":"2024","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.jcf.2025.03.007_bib0014","article-title":"Preumont V. Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes","volume":"33","author":"Lurquin","year":"2023","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.jcf.2025.03.007_bib0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clnesp.2023.08.028","article-title":"Effect of 18 months elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosis","volume":"58","author":"Taelman","year":"2023","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.jcf.2025.03.007_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155330","article-title":"Risk of incident diabetes after COVID-19 infection: a systematic review and meta-analysis","volume":"137","author":"Lai","year":"2022","journal-title":"Metabolism"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932500075X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932500075X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:14:37Z","timestamp":1778822077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932500075X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S156919932500075X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.03.007","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemoglobin A1c in youth and adults with cystic fibrosis related diabetes decreases after elexacaftor-tezacaftor-ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}